Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | CALML3 | P27482 | 1/20 | 0.55 |
| ▸ | SDHA | P31040 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 12/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725608 | 1.00 | MAOB (0.56) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL1498671 | 0.91 | MAOB (0.67) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5323788 | 0.91 | MAOB (0.67) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL10151560 | 0.88 | MAOB (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL6229500 | 0.88 | MAOB (0.56) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL10151452 | 0.87 | MAOB (0.62) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL12665684 | 0.86 | MAOB (0.56) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5327254 | 0.85 | MAOB (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL1498683 | 0.85 | MAOB (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL4173980 | 0.85 | MAOA (0.60) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328509-B1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6998420-B2 | Oxazolidinone compounds | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | TET1, NAT10, TET3 | MAOB 3604/4885MAOA 3886/4885LMNA 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.